Literature DB >> 22223866

Value-based insurance design: aligning incentives, benefits, and evidence in oncology.

Jonas A de Souza1, Mark J Ratain, A Mark Fendrick.   

Abstract

When everyone is required to pay the same out-of-pocket amount for oncology services for which benefits depend on patient characteristics and clinical indication, there is enormous potential for both under- and overutilization. Unlike most current health plan designs, the value-based insurance design (V-BID) explicitly acknowledges and responds to patient heterogeneity across the entire continuum of cancer care. By adding "clinical nuance" to benefit design, V-BID encourages the use of services when the clinical benefits exceed the cost, and likewise discourages the use of services when the benefits do not justify the expenditure. This manuscript further describes the concept of V-BID, creates a framework for its development in oncology, and outlines how this concept aligns with ongoing research, care delivery, and payment reform initiatives.

Entities:  

Mesh:

Year:  2012        PMID: 22223866     DOI: 10.6004/jnccn.2012.0005

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  8 in total

1.  The imperative to address the cost of oncology care.

Authors:  Neal J Meropol
Journal:  J Natl Cancer Inst       Date:  2013-11-13       Impact factor: 13.506

Review 2.  Perioperative systemic nonsteroidal anti-inflammatory drugs (NSAIDs) in women undergoing breast surgery.

Authors:  Kevin M Klifto; Ala Elhelali; Rachael M Payne; Carisa M Cooney; Michele A Manahan; Gedge D Rosson
Journal:  Cochrane Database Syst Rev       Date:  2021-11-09

3.  Hypofractionated Radiation Therapy for Breast Cancer: Financial Risk and Expenditures in the United States, 2008 to 2017.

Authors:  Loren Saulsberry; Chuanhong Liao; Dezheng Huo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-10-09       Impact factor: 8.013

4.  Cost and Complications of Local Therapies for Early-Stage Breast Cancer.

Authors:  Benjamin D Smith; Jing Jiang; Ya-ChenTina Shih; Sharon H Giordano; Jinhai Huo; Reshma Jagsi; Adeyiza O Momoh; Abigail S Caudle; Kelly K Hunt; Simona F Shaitelman; Thomas A Buchholz; Shervin M Shirvani
Journal:  J Natl Cancer Inst       Date:  2016-09-27       Impact factor: 13.506

5.  Cancer patients' trade-offs among efficacy, toxicity, and out-of-pocket cost in the curative and noncurative setting.

Authors:  Yu-Ning Wong; Brian L Egleston; Kush Sachdeva; Naa Eghan; Melanie Pirollo; Tammy K Stump; John Robert Beck; Katrina Armstrong; Jerome Sanford Schwartz; Neal J Meropol
Journal:  Med Care       Date:  2013-09       Impact factor: 2.983

6.  Real-world testing and treatment patterns in chronic lymphocytic leukemia: A SEER patterns of care analysis.

Authors:  Erlene K Seymour; Julie J Ruterbusch; Jennifer L Beebe-Dimmer; Charles A Schiffer
Journal:  Cancer       Date:  2018-10-21       Impact factor: 6.860

7.  Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options.

Authors:  Rositsa Koleva-Kolarova; James Buchanan; Heleen Vellekoop; Simone Huygens; Matthijs Versteegh; Maureen Rutten-van Mölken; László Szilberhorn; Tamás Zelei; Balázs Nagy; Sarah Wordsworth; Apostolos Tsiachristas
Journal:  Appl Health Econ Health Policy       Date:  2022-04-04       Impact factor: 3.686

8.  Health Care Expenditure Burden of Cancer Care in the United States.

Authors:  Joohyun Park; Kevin A Look
Journal:  Inquiry       Date:  2019 Jan-Dec       Impact factor: 1.730

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.